Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 12/20 | 0.80 |
| ▸ | NPY4R | P50391 | 8/20 | 0.80 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.80 |
| ▸ | NPY1R | P25929 | 6/20 | 0.80 |
| ▸ | CALCR | P30988 | 4/20 | 0.68 |
| ▸ | TFPI | P10646 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496288 | 0.96 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29397746 | 0.96 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29496391 | 0.95 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30121639 | 0.93 | NPY2R (0.92) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| Human Neuropeptide Y SCHEMBL29523348 | 0.92 | CALCR (0.72) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29571016 | 0.92 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30001037 | 0.92 | CALCR (0.78) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30001479 | 0.92 | CALCR (0.80) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31744322 | 0.91 | CALCR (0.77) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29526997 | 0.91 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026099341-A1 | BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS | SNIPR BIOME APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739777-A1 | TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260097101-A1 | Compositions for Use in the Treatment of Diabetes or Obesity | DIA BETA LABS LTD (IE) | 2026-04-09 | — | — | US | disclosed |
| EP-4714494-A2 | A MYOSTATIN PATHWAY INHIBITOR IN COMBINATION WITH A GLP-1 PATHWAY ACTIVATOR FOR USE IN TREATING METABOLIC DISORDERS | Scholar Rock, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559529-B2 | NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-3965761-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040070-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | US | disclosed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | NPY2R 4154/4885NPY4R 4018/4885NPY5R 4436/4885 |
| US-20220056017-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | NPY2R 7/4885NPY4R 14/4885NPY5R 12/4885 |
| US-20220041678-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | NPY2R 1/4885NPY4R 4/4885NPY5R 3/4885 |
| US-12559529-B2 | NPY2 receptor agonists | NPY2R, NPY5R, NPY1R | NPY2R 1/4885NPY4R 4/4885NPY5R 2/4885 |
| US-20260097101-A1 | Compositions for Use in the Treatment of Diabetes or Obesity | NPY4R, NPY5R, NPY1R | NPY2R 4/4885NPY4R 1/4885NPY5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.